Background to the Motilent study

Crohn’s disease is a painful, lifelong inflammatory condition of the gut that affects around 92,000 people in the UK. Treating Crohn's involves controlling inflammation with medication to improve symptoms and prevent long-term damage. However, patients without inflammation do not benefit from medication, and even when inflammation is present up to 40% of people don't respond or lose response meaning that their treatment fails. 

The medications can also cause severe side effects and are expensive, costing around £400m a year. 

Why is the Motilent study needed?

Medication would be better targeted if we initially identify patients who may benefit, and then quickly select those in whom it is not working so they can be switched to an alternative therapy. There is therefore a need to develop a tool that can reliably detect inflammation as well as monitor and predict treatment effects.

What will happen during the Motilent study?

The movement of the gut, known as its motility, becomes abnormal in Crohn's disease. Research has shown that the more inflamed the bowel is, the less well it moves but that motility can recover quickly when therapy works. The technology company Motilent has developed GIQuantTM, a new software that allows measurements of gut motility by MRI scanning. MRI scanning is routinely used within the NHS. 

What can being involved in the Motilent study help to achieve?

Motilent’s technology could be used in hospitals without new equipment or intensive training. It could shorten the total scan time by up to 20 minutes and avoid contrast injections, reducing costs and improving the experience for patients. 

How can you be involved in Motilent?

We are currently looking for a number of individuals who have Crohn's to help to deliver the study in a way that is acceptable to patients, this will be our focus group

Our focus group will meet twice during each year of the project - up to 4 times in total with each meeting lasting around 2 hours. They will be asked to consider issues relating to the design and delivery of the study and any materials intended for use by patients being invited to join the study. Focus group members will also help with an event to disseminate the results of the study at the end.

You may also be considered to join the trial if you have a diagnosis of Crohn's disease.

I'd like to be considered as a trial participant Register here
I'd like to help with public involvement in this study Register here